AC
VKTX icon

Avestar Capital’s Viking Therapeutics VKTX Stock Holding History

Avestar Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-388
Closed -$3K – 812
2019
Q2 		$3K Hold
388
– – ﹤0.01% 651
2019
Q1 		$3K Hold
388
– – ﹤0.01% 631
2018
Q4 		$2K Buy
+388
New +$4.64K ﹤0.01% 657

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Avestar Capital's VKTX Position: Q3 2019 in Review

Avestar Capital sold out of Viking Therapeutics (VKTX) in Q3 2019, closing a stake of 388 shares — an estimated $3K sold.

Avestar Capital first reported a position in VKTX in Q4 2018 and held it in 3 quarters. The position peaked at $3K in Q2 2019. 144 funds tracked by Wall St. Rank hold VKTX as of Q3 2019.

  • Avestar Capital reported no remaining Viking Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Avestar Capital sold 388 Viking Therapeutics shares in Q3 2019, an estimated $3K.
  • Avestar Capital first reported a position in Viking Therapeutics in Q4 2018 and held it in 3 quarters.
  • Avestar Capital's Viking Therapeutics position peaked at $3K in Q2 2019.
  • 144 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2019.

Based on Avestar Capital's 13F filing for Q3 2019, filed 14 Nov 2019.